MX337666B - Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas. - Google Patents

Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.

Info

Publication number
MX337666B
MX337666B MX2012004619A MX2012004619A MX337666B MX 337666 B MX337666 B MX 337666B MX 2012004619 A MX2012004619 A MX 2012004619A MX 2012004619 A MX2012004619 A MX 2012004619A MX 337666 B MX337666 B MX 337666B
Authority
MX
Mexico
Prior art keywords
oncogenic fusion
fusion proteins
present
proximity
detecting
Prior art date
Application number
MX2012004619A
Other languages
English (en)
Other versions
MX2012004619A (es
Inventor
Sharat Singh
Xinjun Liu
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2012004619A publication Critical patent/MX2012004619A/es
Publication of MX337666B publication Critical patent/MX337666B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención se refiere a matrices basadas en anticuerpos para detectar el estado de activación cantidad total y/o cantidad total de una o una pluralidad de proteínas de fusión oncogénicas en una muestra biológica como sangre con todas sus fracciones o tejido tumoral y métodos de uso de lo mismo. En ciertos casos, el estado de activación y/o la cantidad total de proteínas de fusión oncogénicas presentes en una muestra puede cuantificarse combinada con una o una pluralidad de moléculas de la transducción de señal. Las composiciones y métodos de la presente invención tienen las ventajas de especificidad asociada a ensayos de inmunoabsorción enzimática, sensibilidad asociada con amplificación de la señal y multiplexión de alto rendimiento asociada con micromatrices.
MX2012004619A 2009-10-20 2010-10-20 Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas. MX337666B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25339309P 2009-10-20 2009-10-20
US30508410P 2010-02-16 2010-02-16
US32748710P 2010-04-23 2010-04-23
US38303710P 2010-09-15 2010-09-15
PCT/US2010/053386 WO2011050069A1 (en) 2009-10-20 2010-10-20 Proximity-mediated assays for detecting oncogenic fusion proteins

Publications (2)

Publication Number Publication Date
MX2012004619A MX2012004619A (es) 2012-05-08
MX337666B true MX337666B (es) 2016-03-14

Family

ID=43242385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004619A MX337666B (es) 2009-10-20 2010-10-20 Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.

Country Status (16)

Country Link
US (1) US20120277109A1 (es)
EP (1) EP2491385B1 (es)
JP (3) JP5819307B2 (es)
KR (1) KR20120110168A (es)
CN (1) CN102667478B (es)
AU (1) AU2010310746B2 (es)
BR (1) BR112012009296A2 (es)
CA (1) CA2777934A1 (es)
DK (1) DK2491385T3 (es)
ES (1) ES2637853T3 (es)
IL (1) IL219313A (es)
MX (1) MX337666B (es)
NZ (1) NZ599460A (es)
RU (1) RU2558797C2 (es)
WO (1) WO2011050069A1 (es)
ZA (1) ZA201202957B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120065092A1 (en) * 2010-09-14 2012-03-15 Wai Hobert Fusion analyte cytometric bead assay, and systems and kits for performing the same
KR20140002711A (ko) 2010-12-23 2014-01-08 네스텍 소시에테아노님 항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
EP2681552A2 (en) 2011-03-02 2014-01-08 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
CN102676648A (zh) * 2011-03-07 2012-09-19 重庆医科大学附属儿童医院 白血病诊疗的基因芯片
ES2639650T3 (es) 2011-04-04 2017-10-27 Pierian Holdings, Inc. Métodos para predecir y mejorar la supervivencia de pacientes con cáncer gástrico
RU2013154566A (ru) 2011-05-10 2015-06-20 Нестек С.А. Способы анализа профиля активности болезни с целью проведения индивидуального лечения
WO2012155019A1 (en) * 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
WO2013049398A2 (en) * 2011-09-28 2013-04-04 H. Lee Moffitt Cancer Center & Research Institute, Inc. Protein-protein interaction as biomarkers
US9335292B2 (en) 2011-10-13 2016-05-10 Auburn University Electrochemical proximity assay
WO2013086031A1 (en) 2011-12-05 2013-06-13 Nestec S.A. Method of therapy selection for patients with cancer
JP6517018B2 (ja) * 2012-02-09 2019-05-22 ヴァー２・ファーマシューティカルズ・アンパルトセルスカブＶＡＲ２ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＡｐＳ コンドロイチン硫酸グリカンのターゲティング
US10041950B2 (en) 2012-03-27 2018-08-07 Ventana Medical Systems, Inc. Signaling conjugates and methods of use
JP2014030572A (ja) * 2012-08-03 2014-02-20 Akira Sakai 抗がん剤投与装置
US9422602B2 (en) 2012-08-15 2016-08-23 Bio-Rad Laboratories, Inc. Methods and compositions for determining nucleic acid degradation
SG11201502646RA (en) 2012-10-05 2015-05-28 Nestec Sa Methods for predicting and monitoring mucosal healing
CN103792364B (zh) * 2012-10-31 2016-06-08 张宝弘 用于检测外周血中循环肿瘤细胞ror1蛋白的试剂及其应用
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
WO2014122599A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
EP2954068B8 (en) 2013-02-05 2018-10-31 Pierian Holdings, Inc. Drug selection for non-small cell lung cancer therapy
CN104007257B (zh) * 2013-02-24 2017-02-08 北京莱尔生物医药科技有限公司 一种检测非体液性稀有有核细胞的方法和试剂盒
WO2014141306A2 (en) * 2013-03-15 2014-09-18 Rajiv Gandhi Centre For Biotechnology Methods and materials for identifying therapeutic response in chronic myeloid leukemia
KR20160009070A (ko) 2013-05-21 2016-01-25 네스텍 소시에테아노님 대장암 환자의 생존율 예측 및 개선 방법
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
GB2524519B (en) * 2014-03-25 2019-11-06 Pelago Bioscience AB Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay
WO2016000966A1 (en) * 2014-06-30 2016-01-07 Nestec S.A. Collaborative enzyme enhanced reactive (ceer) immunoassay using flow cytometry
EP3210016A1 (en) 2014-10-20 2017-08-30 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
US11149299B2 (en) * 2015-06-25 2021-10-19 Ramesh Vallabhaneni Method and system for multiplex profiling of chromosomes in biological samples using target-specific DNA probes
TWI734775B (zh) * 2016-04-26 2021-08-01 美商美國泰福生技股份有限公司 細胞培養基
CN106645728A (zh) * 2016-11-09 2017-05-10 百奥森（江苏）食品安全科技有限公司 一种食品中氟喹诺酮类药物的检测试剂盒
CN110191705A (zh) * 2016-12-01 2019-08-30 亚尼塔公司 治疗癌症的方法
US10852274B2 (en) 2017-03-09 2020-12-01 Auburn University Differential circuit for background correction in electrochemical measurements
KR20180117529A (ko) * 2017-04-19 2018-10-29 주식회사 프로티나 단백질-단백질 상호작용 분석에 의한 약물 반응성 예측 방법
EP3612843A1 (en) 2017-05-31 2020-02-26 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in crohn's disease patients
US11505799B2 (en) 2017-07-07 2022-11-22 Innamed, Inc. Aptamers for measuring lipoprotein levels
US11560565B2 (en) 2018-06-13 2023-01-24 Auburn University Electrochemical detection nanostructure, systems, and uses thereof
CN109439759A (zh) * 2018-12-18 2019-03-08 武汉迪安医学检验实验室有限公司 一种用于检测CBFβ-MYH11融合基因的试剂盒
WO2020140927A1 (en) * 2019-01-02 2020-07-09 Crownmab Biotech Inc. Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers
WO2023286723A1 (ja) 2021-07-13 2023-01-19 キヤノン株式会社 検体の分析方法および検体分析装置
WO2023058624A1 (ja) * 2021-10-08 2023-04-13 コニカミノルタ株式会社 染色方法、評価方法および標本

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197199A (en) 1977-10-25 1980-04-08 Manor Engineering Company Limited Filter presses
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992021032A1 (en) 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス，インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
US5728868A (en) 1993-07-15 1998-03-17 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
WO1995004136A1 (en) * 1993-07-29 1995-02-09 Cor Therapeutics, Inc. Receptor function assays
JP3498960B2 (ja) 1993-09-03 2004-02-23 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 蛍光酸素チャンネリングイムノアッセイ
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6107457A (en) 1995-02-16 2000-08-22 Board Of Regents, The University Of Texas System Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
PL190489B1 (pl) 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
DK0983510T3 (da) * 1997-05-20 2004-07-05 Univ Erasmus Genkendelse af tumorspecifikke genprodukter i cancer
US6686165B2 (en) 1997-05-20 2004-02-03 Erasmus Universiteit Rotterdam Recognition of tumor-specific gene products in cancer
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6897073B2 (en) 1998-07-14 2005-05-24 Zyomyx, Inc. Non-specific binding resistant protein arrays and methods for making the same
US6780582B1 (en) 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001000207A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
EP1194152A4 (en) 1999-06-30 2002-11-06 Merck & Co Inc SIN KINASE INHIBITOR COMPOUNDS
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
BR0013899A (pt) 1999-09-10 2003-07-08 Merck & Co Inc Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral
BR0014843A (pt) 1999-10-19 2002-06-11 Merck & Co Inc Composto, composição farmacêutica, métodos para tratar ou prevenir o câncer em um mamìfero, uma doença em que a angiogênese está implicada, a vascularização retinal, a retinipatia diabética, a degeneração macular relacionada com a idade, doença inflamatória, uma doença ou condição dependente de tirosina quinase e, patologias relacionadas com o osso, processo para fabricar uma composição farmacêutica, e, método para reduzir ou impedir o dano de tecido que segue um evento isquêmico
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2001277245A1 (en) 2000-08-03 2002-02-18 Massachusetts Institute Of Technology Microarrays of functional biomolecules, and uses therefor
US20020132274A1 (en) * 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
US6777239B2 (en) 2001-04-17 2004-08-17 Xenoport, Inc. Epitope-captured antibody display
ATE316088T1 (de) 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20030153013A1 (en) 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
US7354773B2 (en) * 2003-05-14 2008-04-08 Beckman Coulter, Inc. Method and apparatus for preparing cell samples for intracellular antigen detection using flow cytometry
EP1507147A1 (en) 2003-08-12 2005-02-16 Erasmus University Medical Center Rotterdam Method for detecting low levels of a fusion protein
US20050214301A1 (en) 2004-03-24 2005-09-29 Cell Signaling Technology, Inc. Antibodies specific for BCR-ABL fusion protein and uses thereof
US20060263837A1 (en) 2004-06-17 2006-11-23 Liu George D Immunoassay system and method for detection of antigens
US7771955B2 (en) 2005-06-09 2010-08-10 University Of Maryland Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
DE212006000071U1 (de) * 2005-11-18 2008-07-24 Board of Regents, The University of Texas System, Austin Quantifizierung von Fusionsproteinen und ihrer Aktivität in Folge chromosomaler Translokation
KR101485303B1 (ko) 2006-09-21 2015-01-22 네스텍 소시에테아노님 희귀 순환세포 내의 다수의 신호전달인자를 검출하기 위한 항체 기반 분석법
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
US9250243B2 (en) 2006-09-21 2016-02-02 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
JP2008261764A (ja) * 2007-04-13 2008-10-30 Kyowa Hakko Kogyo Co Ltd キナーゼ阻害物質の測定方法
GB0714573D0 (en) * 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2860247A1 (en) * 2007-08-21 2015-04-15 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
JP5228416B2 (ja) * 2007-09-12 2013-07-03 株式会社リコー 定電流出力制御型スイッチングレギュレータ
WO2009108637A1 (en) * 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
EP2108956A1 (en) * 2008-04-07 2009-10-14 Erasmus University Medical Center Rotterdam Improved methods and kits for detecting tumor-specific fusion proteins
US8301258B2 (en) 2008-08-14 2012-10-30 The Chinese University Of Hong Kong Methods and devices for preventing ankle sprain injuries

Also Published As

Publication number Publication date
BR112012009296A2 (pt) 2021-02-02
ZA201202957B (en) 2017-01-25
AU2010310746B2 (en) 2015-07-23
CA2777934A1 (en) 2011-04-28
RU2558797C2 (ru) 2015-08-10
JP2016028251A (ja) 2016-02-25
CN102667478A (zh) 2012-09-12
JP2018119975A (ja) 2018-08-02
EP2491385B1 (en) 2017-05-10
RU2012120722A (ru) 2013-11-27
JP2013508728A (ja) 2013-03-07
AU2010310746A1 (en) 2012-05-03
IL219313A (en) 2017-03-30
IL219313A0 (en) 2012-06-28
NZ599460A (en) 2014-07-25
EP2491385A1 (en) 2012-08-29
WO2011050069A1 (en) 2011-04-28
US20120277109A1 (en) 2012-11-01
KR20120110168A (ko) 2012-10-09
CN102667478B (zh) 2018-06-01
JP5819307B2 (ja) 2015-11-24
ES2637853T3 (es) 2017-10-17
JP6301892B2 (ja) 2018-03-28
MX2012004619A (es) 2012-05-08
DK2491385T3 (en) 2017-08-28

Similar Documents

Publication Publication Date Title
MX337666B (es) Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas.
WO2008021290A3 (en) Organ-specific proteins and methods of their use
MX2010009766A (es) Ensayo de proteasa.
WO2008070865A3 (en) Materials and methods for efficient and accurate detection of analytes
ES2570731T3 (es) Método de detección de cáncer
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
TW200720441A (en) New labelling strategies for the sensitive detection of analytes
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
UA116618C2 (uk) СКОНСТРУЙОВАНЕ НА ОСНОВІ ЦИСТЕЇНУ АНТИТІЛО ПРОТИ CD79b
ATE554389T1 (de) Apex als marker für lungenkrebs
EP1930445A4 (en) KIT AND METHOD FOR DETECTING UROTHELIAL CANCER
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
WO2010046443A3 (en) Methods for detection and diagnosis of a bone or cartilage disorder
TR201907065T4 (tr) Aptamer kullanarak hedef maddeyi tespit yöntemi.
CY1112553T1 (el) Ανοσοπροσδιορισμοι υψηλης ευαισθησιας και κιτια για τον προσδιορισμο πεπτιδιων και πρωτεϊνων βιολογικου ενδιαφεροντος
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2011036666A3 (en) Systems and methods for measuring translation of target proteins in cells
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
WO2011008814A3 (en) Multiplexed measurement of exogenous and endogenous dna
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
DE60306865D1 (de) Detektion von Vancomycin-resistenten Enterococcus-Subspezies
WO2010000467A8 (en) Asc as a marker for lung cancer
MX341181B (es) Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NESTEC S.A.

FG Grant or registration